Inhibrx Biosciences Q3 2026 Revenue Tops Estimates at $2.0M, but EPS Misses at -$2.46
Revenue of $2.0M vs. $1.9M expected and adjusted EPS of -$2.46 vs. -$2.45.
Inhibrx Biosciences (INBX) posted mixed third-quarter 2026 results, with revenue above the estimate and adjusted EPS below it. Revenue was $2.0 million above the $1.9 million estimate, and adjusted EPS was -$2.46, down 7.9% from a year earlier, below the -$2.45 estimate.
Shares were unchanged in after-hours trading as of 4:00 p.m. ET, to $83.30 from a $83.30 close.
Q3 2026 scorecard
| Parameters | Expected | Actual | Beat/Miss |
|---|---|---|---|
| Adjusted EPS | -$2.45 | -$2.46 | Miss by 0.4% |
| Revenue | $1.9M | $2.0M | Beat by 5.3% |
By our calculation, revenue was $100 thousand above the estimate and adjusted EPS was $0.01 below it.
Track record
- EPS record. Adjusted EPS beat the estimate in 2 of the last 8 reports, including this one.
What to watch
- Next-quarter estimates. Consensus calls for EPS of -$2.70 and revenue of $2.4 million next quarter, based on 2 analysts.
- Estimate record. Whether Inhibrx Biosciences returns to beating EPS estimates, which it did in 2 of its last 8 reports.
- Share reaction. How shares trade in the next regular session after the 0.0% gain in after-hours trading.
- Related coverage. See our reports on HawkEye 360, Almonty Industries, TMC the metals and Nu.
Sources: Results are from Inhibrx Biosciences's Nov. 13, 2026 quarterly report. Estimates are consensus figures. The prior-quarter and year-ago comparison figures are from Inhibrx Biosciences's earlier quarterly reports. Items labeled by our calculation are our own arithmetic. This article is informational only and is not investment advice.
Readers also read
MarketCatalyst is not a registered investment advisor and does not manage client assets. Content on this platform is provided for informational and educational purposes only. It is not investment advice, and MarketCatalyst is not a stock-picking or trade-alert service. Trading stocks and options involves risk, including the possible loss of principal. Consider your own goals, time horizon, and risk tolerance, and consult a qualified financial advisor before making any investment decision.
